David Scott Miller

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi request reprint Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study
    David Scott Miller
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas, Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, J7 124, Dallas, TX 75390 9032, USA
    Gynecol Oncol 98:217-21. 2005
  2. doi request reprint A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology
    David Scott Miller
    Division of Gynecologic Oncology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Room J7 124, Dallas, TX 75390 9032, USA
    Gynecol Oncol 115:443-6. 2009
  3. doi request reprint Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
    David Scott Miller
    University of Texas Southwestern Medical Center at Dallas, TX 75390 9032, USA
    Gynecol Oncol 110:65-70. 2008
  4. ncbi request reprint Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, J7 124, Dallas, TX 75390, USA
    Gynecol Oncol 96:67-71. 2005
  5. pmc Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group
    David S Miller
    University of Texas Southwestern Medical Center at Dallas, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Dallas, TX 75390 9032, USA
    J Clin Oncol 27:2686-91. 2009
  6. ncbi request reprint Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Cancer 98:1664-9. 2003
  7. ncbi request reprint A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Gynecol Oncol 87:247-51. 2002
  8. doi request reprint Pharmacotherapy of endometrial cancer
    Nicanor I Barrena Medel
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, USA
    Expert Opin Pharmacother 10:1939-51. 2009
  9. ncbi request reprint Other primary malignancies in patients with uterine corpus malignancy
    Jacquelyn B Delin
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Am J Obstet Gynecol 190:1429-31. 2004
  10. pmc Gynecologic oncology group trials in uterine corpus malignancies: recent progress
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Gynecol Oncol 19:218-22. 2008

Detail Information

Publications16

  1. ncbi request reprint Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study
    David Scott Miller
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas, Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, J7 124, Dallas, TX 75390 9032, USA
    Gynecol Oncol 98:217-21. 2005
    ....
  2. doi request reprint A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology
    David Scott Miller
    Division of Gynecologic Oncology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Room J7 124, Dallas, TX 75390 9032, USA
    Gynecol Oncol 115:443-6. 2009
    ..To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the endometrium and to determine the nature and degree of toxicity...
  3. doi request reprint Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
    David Scott Miller
    University of Texas Southwestern Medical Center at Dallas, TX 75390 9032, USA
    Gynecol Oncol 110:65-70. 2008
    ..To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity...
  4. ncbi request reprint Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, J7 124, Dallas, TX 75390, USA
    Gynecol Oncol 96:67-71. 2005
    ..To estimate the antitumor activity of 9-aminocamptothecin (9-AC) in patients with recurrent platinum-"resistant" ovarian cancer; and to determine the nature and degree of toxicity of 9-AC in this cohort of patients...
  5. pmc Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group
    David S Miller
    University of Texas Southwestern Medical Center at Dallas, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Dallas, TX 75390 9032, USA
    J Clin Oncol 27:2686-91. 2009
    ..To estimate the antitumor activity of pemetrexed in patients with persistent or recurrent platinum-resistant epithelial ovarian or primary peritoneal cancer and to determine the nature and degree of toxicities...
  6. ncbi request reprint Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Cancer 98:1664-9. 2003
    ..Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability and antitumor activity of a 3-day topotecan regimen...
  7. ncbi request reprint A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Gynecol Oncol 87:247-51. 2002
    ....
  8. doi request reprint Pharmacotherapy of endometrial cancer
    Nicanor I Barrena Medel
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, USA
    Expert Opin Pharmacother 10:1939-51. 2009
    ..The lack of an effective, standardized adjuvant treatment for women at a high risk of recurrence has contributed to these disappointing results...
  9. ncbi request reprint Other primary malignancies in patients with uterine corpus malignancy
    Jacquelyn B Delin
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
    Am J Obstet Gynecol 190:1429-31. 2004
    ..The purpose of this study was to determine the occurrence of multiple primary malignancies in patients with uterine corpus malignancy...
  10. pmc Gynecologic oncology group trials in uterine corpus malignancies: recent progress
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Gynecol Oncol 19:218-22. 2008
    ..This article will discuss the background and details of each of these important advances...
  11. ncbi request reprint Recent progress: gynecologic oncology group trials in uterine corpus tumors
    Louise P King
    University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9032, USA
    Rev Recent Clin Trials 4:70-4. 2009
    ..This article will discuss the background and details of each of these important advances...
  12. ncbi request reprint Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer
    David Scott Miller
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Natl Compr Canc Netw 7:535-41. 2009
    ..Recent studies have suggested an expanded role for chemotherapy and questioned the benefit of radiation therapy. Ongoing and planned clinical trials should provide clarification...
  13. ncbi request reprint Hormonal therapy in epithelial ovarian cancer
    Gautam G Rao
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, B 1100 MCN, Nashville, TN 37232 2516, USA
    Expert Rev Anticancer Ther 6:43-7. 2006
    ....
  14. ncbi request reprint Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study
    Agustin A Garcia
    Breast Cancer Program, Cedars Sinai Medical Center, Women s Cancer Research Institute, 8700 Beverly Boulevard Room 290 W, Los Angeles, CA 90048, USA
    Gynecol Oncol 96:810-7. 2005
    ....
  15. ncbi request reprint Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Franco M Muggia
    Division of Medical Oncology, Department of Medicine, Kaplan Cancer Center, New York University Medical Center, New York, NY 10016, USA
    Gynecol Oncol 92:639-43. 2004
    ..The objective of this Phase II trial was to evaluate a days 1 and 8 every-21-days schedule and determine its activity in patients who had failed standard chemotherapy...
  16. ncbi request reprint Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study
    John H Edmonson
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905 0001, USA
    Gynecol Oncol 85:507-10. 2002
    ....